Free Trial

Nuvation Bio (NUVB) Stock Price, News & Analysis

-0.22 (-6.71%)
(As of 03:32 PM ET)
Today's Range
50-Day Range
52-Week Range
609,894 shs
Average Volume
1.19 million shs
Market Capitalization
$667.23 million
P/E Ratio
Dividend Yield
Price Target

Nuvation Bio MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
105.0% Upside
$6.60 Price Target
Short Interest
2.51% of Float Sold Short
Dividend Strength
News Sentiment
0.49mentions of Nuvation Bio in the last 14 days
Based on 11 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($0.32) to ($0.45) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.26 out of 5 stars

Medical Sector

289th out of 921 stocks

Pharmaceutical Preparations Industry

123rd out of 426 stocks

NUVB stock logo

About Nuvation Bio Stock (NYSE:NUVB)

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.

NUVB Stock Price History

NUVB Stock News Headlines

Nuvation Bio (NYSE:NUVB) Stock Rating Reaffirmed by HC Wainwright
Nuvation Bio (NYSE:NUVB) Rating Reiterated by Wedbush
Nuvation Bio Inc (NUVB)
NUVB Apr 2024 2.000 put
NUVB Apr 2024 0.500 call
See More Headlines
Receive NUVB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nuvation Bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
5 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$2.72 per share


Free Float
Market Cap
$699.94 million
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Dr. David T. Hung M.D.Dr. David T. Hung M.D. (Age 66)
    Founder, President, CEO & Director
    Comp: $1M
  • Dr. Gary Hattersley Ph.D. (Age 57)
    Chief Scientific Officer
    Comp: $694.56k
  • Dr. David Liu M.D. (Age 54)
    Ph.D., Chief Medical Officer
    Comp: $677.15k
  • Mr. Moses Makunje CPA (Age 45)
    VP of Finance and Principal Accounting & Financial Officer
  • Ms. Stacy Markel (Age 59)
    Chief People Officer
  • Dr. David C. Hanley Ph.D. (Age 54)
    Chief Technical Operations Officer
    Comp: $586.04k
  • Ms. Kerry A. Wentworth (Age 51)
    Chief Regulatory Officer
  • Ms. Colleen Sjogren (Age 54)
    Chief Commercial Officer
  • Dr. Junyuan Wang Ph.D. (Age 51)
    CEO & Co-Founder of AnHeart Therapeutics and Director

NUVB Stock Analysis - Frequently Asked Questions

Should I buy or sell Nuvation Bio stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nuvation Bio in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" NUVB shares.
View NUVB analyst ratings
or view top-rated stocks.

What is Nuvation Bio's stock price target for 2024?

5 analysts have issued 12-month price objectives for Nuvation Bio's stock. Their NUVB share price targets range from $5.00 to $10.00. On average, they predict the company's stock price to reach $6.60 in the next year. This suggests a possible upside of 105.0% from the stock's current price.
View analysts price targets for NUVB
or view top-rated stocks among Wall Street analysts.

How have NUVB shares performed in 2024?

Nuvation Bio's stock was trading at $1.51 at the beginning of the year. Since then, NUVB shares have increased by 113.2% and is now trading at $3.22.
View the best growth stocks for 2024 here

When is Nuvation Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024.
View our NUVB earnings forecast

How were Nuvation Bio's earnings last quarter?

Nuvation Bio Inc. (NYSE:NUVB) posted its quarterly earnings results on Thursday, February, 29th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.04.

What ETFs hold Nuvation Bio's stock?

ETFs with the largest weight of Nuvation Bio (NYSE:NUVB) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Loncar China Biopharma ETF (CHNA).

Who are Nuvation Bio's major shareholders?

Nuvation Bio's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (3.46%), Price T Rowe Associates Inc. MD (0.62%), Acadian Asset Management LLC (0.54%), Jacobs Levy Equity Management Inc. (0.34%), Ikarian Capital LLC (0.29%) and Assenagon Asset Management S.A. (0.26%). Insiders that own company stock include Fund V LP Omega, Kathryn E Falberg and Oleg Nodelman.
View institutional ownership trends

How do I buy shares of Nuvation Bio?

Shares of NUVB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:NUVB) was last updated on 5/23/2024 by Staff

From Our Partners